{
    "id": 10511,
    "fullName": "KIAA1549 - BRAF",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "KIAA1549-BRAF results from the fusion of KIAA1549 and BRAF, leads to increased Braf kinase activity, activation of MAPK signaling, and is transforming in culture (PMID: 18974108, PMID: 23152448). KIAA1549-BRAF has been identified in pilocytic astrocytoma (PMID: 18974108).",
            "references": [
                {
                    "id": 2050,
                    "pubMedId": 23152448,
                    "title": "Pediatric glioma-associated KIAA1549:BRAF expression regulates neuroglial cell growth in a cell type-specific and mTOR-dependent manner.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23152448"
                },
                {
                    "id": 2044,
                    "pubMedId": 18974108,
                    "title": "Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18974108"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 57670,
        "geneSymbol": "KIAA1549",
        "terms": [
            "KIAA1549",
            "RP86"
        ]
    },
    "variant": "KIAA1549 - BRAF",
    "createDate": "08/12/2015",
    "updateDate": "10/18/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 673,
                "geneSymbol": "BRAF",
                "terms": [
                    "BRAF",
                    "B-raf",
                    "B-RAF1",
                    "BRAF1",
                    "NS7",
                    "RAFB1"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 9409,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized KIAA1549-BRAF (PMID: 26343582).",
            "molecularProfile": {
                "id": 10513,
                "profileName": "KIAA1549 - BRAF"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7141,
                    "pubMedId": 26343582,
                    "title": "BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343582"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14106,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) treatment resulted in paradoxical MAPK activation as indicated by increased ERK phosphorylation in pilocytic astrocytoma cells derived from a pediatric patient harboring KIAA1549-BRAF in culture (PMID: 28002790).",
            "molecularProfile": {
                "id": 10513,
                "profileName": "KIAA1549 - BRAF"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 6812,
                "name": "childhood pilocytic astrocytoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11078,
                    "pubMedId": 28002790,
                    "title": "Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28002790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5662,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with a malignant spindle cell tumor harboring KIAA1549-BRAF responded to treatment with Nexavar (sorafenib) in combination with Avastin (bevacizumab) and Torisel (temsirolimus) (PMID: 26314551).",
            "molecularProfile": {
                "id": 10513,
                "profileName": "KIAA1549 - BRAF"
            },
            "therapy": {
                "id": 3917,
                "therapyName": "Bevacizumab + Sorafenib + Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 4015,
                "name": "spindle cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5129,
                    "pubMedId": 26314551,
                    "title": "The distribution of BRAF gene fusions in solid tumors and response to targeted therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26314551"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14112,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) treatment resulted in paradoxical MAPK activation as indicated by increased ERK phosphorylation in pilocytic astrocytoma cells derived from a pediatric patient harboring KIAA1549-BRAF in culture (PMID: 28002790).",
            "molecularProfile": {
                "id": 10513,
                "profileName": "KIAA1549 - BRAF"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 6812,
                "name": "childhood pilocytic astrocytoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11078,
                    "pubMedId": 28002790,
                    "title": "Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28002790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9110,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells over expressing KIAA1549-BRAF demonstrated increased sensitivity to Selumetinib (AZD6244) in culture (PMID: 27217440).",
            "molecularProfile": {
                "id": 10513,
                "profileName": "KIAA1549 - BRAF"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6921,
                    "pubMedId": 27217440,
                    "title": "BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27217440"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7903,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX4720 stimulated growth of transformed cell lines over expressing KIAA1549-BRAF in culture through paradoxical activation of Mapk signaling and failed to suppress tumor growth in cell line xenograft models (PMID: 23533272).",
            "molecularProfile": {
                "id": 10513,
                "profileName": "KIAA1549 - BRAF"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2256,
                    "pubMedId": 23533272,
                    "title": "Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23533272"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14109,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAK-632 treatment resulted in paradoxical MAPK activation as indicated by increased ERK phosphorylation in pilocytic astrocytoma cells derived from a pediatric patient harboring KIAA1549-BRAF in culture (PMID: 28002790).",
            "molecularProfile": {
                "id": 10513,
                "profileName": "KIAA1549 - BRAF"
            },
            "therapy": {
                "id": 3300,
                "therapyName": "TAK-632",
                "synonyms": null
            },
            "indication": {
                "id": 6812,
                "name": "childhood pilocytic astrocytoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11078,
                    "pubMedId": 28002790,
                    "title": "Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28002790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7905,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX7904 inhibited soft agar growth of transformed cell lines over expressing KIAA1549-BRAF in culture (PMID: 23533272).",
            "molecularProfile": {
                "id": 10513,
                "profileName": "KIAA1549 - BRAF"
            },
            "therapy": {
                "id": 4606,
                "therapyName": "PLX7904",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2256,
                    "pubMedId": 23533272,
                    "title": "Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23533272"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17682,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "KIAA1549-BRAF fusions aid the diagnosis of pilocytic astrocytoma (NCCN.org).",
            "molecularProfile": {
                "id": 10513,
                "profileName": "KIAA1549 - BRAF"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 4851,
                "name": "pilocytic astrocytoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 14111,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) inhibited ERK phosphorylation, resulted in growth inhibition in pilocytic astrocytoma cells derived from a pediatric patient harboring KIAA1549-BRAF in culture (PMID: 28002790).",
            "molecularProfile": {
                "id": 10513,
                "profileName": "KIAA1549 - BRAF"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 6812,
                "name": "childhood pilocytic astrocytoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11078,
                    "pubMedId": 28002790,
                    "title": "Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28002790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18500,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Selumetinib (AZD6244) treatment resulted in a sustained partial response (PR) in 36% (9/25) and stable disease in 36% (9/25) of pediatric patients with pilocytic astrocytoma harboring KIAA1549-BRAF (n=18) or BRAF V600E (n=7), with a 2-year progression-free survival of 70%, and 39% (7/18) of the patients harboring KIAA1549-BRAF achieved PR (PMID: 31151904; NCT01089101).",
            "molecularProfile": {
                "id": 10513,
                "profileName": "KIAA1549 - BRAF"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 6812,
                "name": "childhood pilocytic astrocytoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16287,
                    "pubMedId": 31151904,
                    "title": "Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31151904"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7277,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, treatment with Selumetinib (AZD-6244) resulted in responses in 21% (8/38) of pediatric patients with low-grade gliomas, with 3 responding patients harboring KIAA1549-BRAF fusions (J Clin Oncol 32:5s, 2014 (suppl; abstr 10065)).",
            "molecularProfile": {
                "id": 10513,
                "profileName": "KIAA1549 - BRAF"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 60108,
                "name": "brain glioma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6285,
                    "pubMedId": null,
                    "title": "A phase 1 study of AZD6244 in children with recurrent or refractory low-grade gliomas: A Pediatric Brain Tumor Consortium report.",
                    "url": "http://meetinglibrary.asco.org/content/134121-144"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14108,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MLN2480 treatment resulted in paradoxical MAPK activation as indicated by increased ERK phosphorylation in pilocytic astrocytoma cells derived from a pediatric patient harboring KIAA1549-BRAF in culture (PMID: 28002790).",
            "molecularProfile": {
                "id": 10513,
                "profileName": "KIAA1549 - BRAF"
            },
            "therapy": {
                "id": 1034,
                "therapyName": "MLN2480",
                "synonyms": null
            },
            "indication": {
                "id": 6812,
                "name": "childhood pilocytic astrocytoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11078,
                    "pubMedId": 28002790,
                    "title": "Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28002790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14110,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited ERK phosphorylation, resulted in growth inhibition in pilocytic astrocytoma cells derived from a pediatric patient harboring KIAA1549-BRAF in culture (PMID: 28002790).",
            "molecularProfile": {
                "id": 10513,
                "profileName": "KIAA1549 - BRAF"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 6812,
                "name": "childhood pilocytic astrocytoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11078,
                    "pubMedId": 28002790,
                    "title": "Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28002790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7904,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX4720 inhibited soft agar growth of transformed cell lines over expressing BRAF R509H in the context of KIAA1549-BRAF in culture and suppressed tumor growth in cell line xenograft models (PMID: 23533272).",
            "molecularProfile": {
                "id": 26094,
                "profileName": "KIAA1549 - BRAF BRAF R509H"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2256,
                    "pubMedId": 23533272,
                    "title": "Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23533272"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 10513,
            "profileName": "KIAA1549 - BRAF",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26094,
            "profileName": "KIAA1549 - BRAF BRAF R509H",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}